FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions 
CRESTWOOD, Ky., Nov. 08, 2017 -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced the pricing of its initial public offering of 10,714,000 shares of common stock at a public offering price of $14.00 per share, for total gross proceeds of approximately $150.0 million, before deducting underwriting discounts and commissions and expenses payable by Apellis. In addition, Apellis has granted the underwriters a 30-day option to purchase up to 1,607,100 additional shares of common stock at the public offering price, less underwriting discounts and commissions, to cover over-allotments, if any. All of the shares are being offered by Apellis. The shares are expected to begin trading on the NASDAQ Global Select Market under the ticker symbol “APLS” on Thursday, November 9, 2017. The offering is expected to close on November 13, 2017, subject to customary closing conditions.
Citigroup, J.P. Morgan and Evercore ISI are acting as joint book-running managers for the offering.
A registration statement relating to the securities being sold in this offering was declared effective by the Securities and Exchange Commission on November 8, 2017. This offering is being made only by means of a prospectus. When available, copies of the final prospectus relating to this offering may be obtained by contacting: Citigroup Global Markets Inc., c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: 1-800-831-9146, or email: [email protected]; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: (866) 803-9204; or Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 36th Floor, New York, NY 10055, telephone: (888) 474-0200, or email: [email protected].
This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Apellis
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
Media Contact: Tully Nicholas [email protected] 617.482.0042 (office) 860.490.0218 (mobile)
